Cathie Wood’s Top 3 Bargain Buys: A Closer Look at the Stocks She Snapped Up on the Dip

Tuesday was a bloodbath for growth investors, with three former high‑flyers—Shopify, Intellia Therapeutics, and GeneDX Holdings—shedding between 4% and 49% of their value. While most traders were running for the exits, Cathie Wood, the visionary CEO of Ark Invest, did exactly the opposite. She added to her firm’s existing positions in all three names, and they were the only stocks Ark Invest purchased that day. What does Wood see that the market is missing? In this listicle, we’ll explore the three stocks she just bought, why they might be bargains, and what it says about her long‑term conviction. Click on any stock below to jump directly to its analysis.

1. Shopify (SHOP) – Betting on the Future of Commerce

Shopify tumbled by about 4% on Tuesday, but Cathie Wood saw an opportunity. The e‑commerce platform has been a favorite of Ark Invest for years, and this dip gave Wood a chance to average down. Shopify enables merchants to build online stores, manage inventory, and process payments. Despite a slowdown in post‑pandemic growth, the company’s fundamentals remain strong: it has a massive addressable market, a sticky ecosystem of apps and partners, and a growing logistics network. Wood likely views the recent pullback as a temporary noise in a long‑term growth story. With the shift to multi‑channel retailing still in its early innings, Shopify is positioned to be a core holding in Ark’s innovation‑focused portfolio. The purchase signals that Wood believes the sell‑off was overdone and that the company’s potential outweighs short‑term headwinds.

2. Intellia Therapeutics (NTLA) – A Biotech Bet on CRISPR

Intellia Therapeutics suffered a steeper decline of roughly 8% on Tuesday. The gene‑editing company is a pioneer in CRISPR therapies, and Wood has long been bullish on the transformative power of genomic medicine. Intellia is developing treatments for genetic diseases using in‑vivo CRISPR editing, meaning the therapy can be delivered directly inside the body. Recent clinical data has been promising, but biotech stocks are notoriously volatile. The Tuesday sell‑off may have been driven by broader risk‑off sentiment rather than company‑specific news. Ark Invest added to its position, betting that the long‑term value of Intellia’s platform will be recognized once more. For Wood, the dip presents an affordable entry point into a company that could revolutionize how we treat conditions like transthyretin amyloidosis and hereditary angioedema. This purchase underscores her conviction that CRISPR stocks are deeply undervalued.

3. GeneDX Holdings (WGS) – Doubling Down on Genomic Testing

The most dramatic fall came from GeneDX Holdings, which plunged a staggering 49% on Tuesday. This genomic diagnostics company specializes in exome and genome sequencing to help diagnose rare diseases. The steep drop followed a lackluster earnings report that disappointed the market. However, Cathie Wood saw a buying opportunity. Ark Invest already held a significant stake and used the crash to increase its position. GeneDX’s technology is critical for precision medicine, and it has a unique database of patient genomic data that grows more valuable over time. While near‑term revenue challenges exist, Wood likely believes the company’s long‑term prospects remain intact. The massive sell‑off may have been an overreaction, and with cash reserves and a recurring revenue model from its diagnostic services, GeneDX could rebound strongly as the genomics sector gains traction. This purchase highlights Wood’s willingness to buy into extreme fear.

Conclusion: Opportunistic, Not Reckless

Cathie Wood’s purchases on Tuesday were not random gambles; they were strategic additions to positions she already believed in. By buying on the dip, she signals that these three stocks are not just short‑term trades but long‑term holdings in her innovation‑themed funds. Shopify benefits from secular e‑commerce trends, Intellia from the gene‑editing revolution, and GeneDX from the expansion of genomic diagnostics. While volatility is certain, Wood’s track record suggests she sees value where others see panic. For investors willing to ride the storm, these three names may offer compelling entry points. As always, caveat emptor—do your own research before following any famous investor into the market.